
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine. Discover how AI is transforming healthcare today, addressing real-world challenges and improving patient outcomes.
This series caters to anyone’s listening style with bite-sized, commute-friendly insights and full-length interviews. Join co-hosts Mika Newton, CEO of xCures, and Dr. Sanjay Juneja, a globally recognized oncologist and VP of Clinical AI at Tempus AI, as they explore cutting-edge innovations with industry pioneers.
Originally launched as the TARGET: Cancer Podcast in 2021, the series evolved after 75 episodes into a comprehensive platform for AI and healthcare conversations.
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine. Discover how AI is transforming healthcare today, addressing real-world challenges and improving patient outcomes.
This series caters to anyone’s listening style with bite-sized, commute-friendly insights and full-length interviews. Join co-hosts Mika Newton, CEO of xCures, and Dr. Sanjay Juneja, a globally recognized oncologist and VP of Clinical AI at Tempus AI, as they explore cutting-edge innovations with industry pioneers.
Originally launched as the TARGET: Cancer Podcast in 2021, the series evolved after 75 episodes into a comprehensive platform for AI and healthcare conversations.
Episodes
Monday May 12, 2025
Monday May 12, 2025
Unlock faster, smarter drug repurposing with open-source data that arms clinicians and researchers with actionable insights. This discussion explores how cutting-edge AI and knowledge graphs are transforming access to potential therapies by ranking 4,000 approved drugs against thousands of diseases - all in record time. Host Dr. Sanjay Juneja speaks with Dr. David Fajgenbaum, Co-founder of Every Cure, to reveal how their platform delivers 75 million computed drug-disease scores directly into the hands of healthcare providers worldwide. Learn how this approach accelerates clinical decision-making, supports evidence-based research, and breaks down barriers to innovative care strategies.

No comments yet. Be the first to say something!